CoChat

Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC

Open access
Yeong, Joe, Suteja, Lisda, Simoni, Yannick, Lau, Kah Weng, Tan, Aaron C., Li, Hui Hua, Lim, Sherlly, Loh, Jie Hua, Wee, Felicia Y.T., Nerurkar, Sanjna Nilesh, Takano, Angela, Tan, Eng Huat, Lim, Tony K.H., Newell, Evan W., Tan, Daniel S.W. · 2021 · Journal of Thoracic Oncology
Cited by 83

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND Programmed cell death-1 (PD-1)/ programmed death-ligand 1 (PD-L1) blockade is currently widely used in the treatment of metastatic non-small cell lung cancer (NSCLC). Despite available biomarker stratification, clinical responses vary. Thus, the search for novel biomarkers with improved response prediction is ongoing. Previously, using mass cytometry deep immune-profiling (CyTOF), our group provided evidence that CD39+CD8+ T cells represent tumor antigen-specific, cytotoxic T cells in treatment-naïve NSCLC. We hypothesized that accurate quantitation of this T cell subset would predict immunotherapy outcome. METHODS In order to translate this to a clinical setting, the present study compared CyTOF data to results obtained via a range of clinically relevant methods; including conventional immunohistochemistry (IHC), multiplex immunohistochemistry/immunofluorescence (mIHC/IF), and gene expression assay by NanoString. RESULTS Quantification using mIHC/IF but not conventional IHC or NanoString correlated with the CyTOF results. The specificity and sensitivity of mIHC/IF was then assessed in a separate retrospective NSCLC cohort. CD39+CD8+ T cell proportion, as determined by mIHC/IF, successfully stratified responders and non-responders to PD-1/PD-L1 inhibitors (Objective Response Rate 63.6%, compared to 0% for the negative group). This predictive capability was independent from other confounding factors, such as total CD8+ T cell proportion, CD39+ lymphocyte proportion, PD-L1 positivity, epidermal growth factor receptor mutation status, and other clinicopathological parameters. CONCLUSION Our results suggest that the mIHC/IF platform is a clinically relevant method to assess CD39+CD8+ T cell proportion and this marker can serve as a potential biomarker that predicts response to PD-1/PD-L1 blockade in NSCLC patients. Further validation in additional NSCLC cohorts is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.04.016

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 83

Metadata

Authors
Yeong, J., Suteja, L., Simoni, Y., Lau, K. W., Tan, A. C., Li, H. H., Lim, S., Loh, J. H., Wee, F. Y. T., Nerurkar, S. N., Takano, A., Tan, E. H., Lim, T. K. H., Newell, E. W., & Tan, D. S. W.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2021-08
Volume
16
Issue
8
Pages
1349-1358
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3161640011
Cited by
83
References
8
FWCI
4.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.